Manhattan Scientifics (Manhattan Scientifics) Cash And Cash Equivalents : $0.05 Mil (As of Mar. 2024)

View and export this data going back to 1998. Start your Free Trial

What is Manhattan Scientifics Cash And Cash Equivalents?

Manhattan Scientifics's quarterly cash and cash equivalents declined from Sep. 2023 ($0.09 Mil) to Dec. 2023 ($0.07 Mil) but then stayed the same from Dec. 2023 ($0.07 Mil) to Mar. 2024 ($0.05 Mil).

Manhattan Scientifics's annual cash and cash equivalents declined from Dec. 2021 ($0.23 Mil) to Dec. 2022 ($0.18 Mil) and declined from Dec. 2022 ($0.18 Mil) to Dec. 2023 ($0.07 Mil).

Manhattan Scientifics Cash And Cash Equivalents Historical Data

The historical data trend for Manhattan Scientifics's Cash And Cash Equivalents can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Manhattan Scientifics Cash And Cash Equivalents Chart

Manhattan Scientifics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Cash And Cash Equivalents

Get a 7-Day Free Trial

0.26

0.35

0.23

0.18

0.07

Manhattan Scientifics Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Cash And Cash Equivalents	Get a 7-Day Free Trial															0.09	0.05	0.09	0.07	0.05

Manhattan Scientifics Cash And Cash Equivalents Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.

Manhattan Scientifics (OTCPK:MHTX) Cash And Cash Equivalents Explanation

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.

Be Aware

Depreciation estimates make the calculation of net income susceptible to management's accounting choices. These choices can be either overly aggressive or overly conservative.

Manhattan Scientifics Cash And Cash Equivalents Related Terms

Thank you for viewing the detailed overview of Manhattan Scientifics's Cash And Cash Equivalents provided by GuruFocus.com. Please click on the following links to see related term pages.

Manhattan Scientifics (Manhattan Scientifics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Manhattan Scientifics Inc (OTCPK:MHTX) » Definitions » Cash And Cash Equivalents

Comparable Companies

Traded in Other Exchanges

N/A

Address

244 Fifth Avenue, Suite 2341, New York, NY, USA, 10001

Website

http://www.mhtx.com

Manhattan Scientifics Inc is a company operating as a technology incubator that seeks to acquire, develop and commercialize life-enhancing technologies in the areas of nano-technologies and nano-medicines. The company continues to identify emerging technologies through strategic alliances with scientific laboratories, educational institutions, and scientists and leaders in industry and government. The company is focused on technology transfer and commercialization of transformative technologies.

Executives

Chris Theoharis	director	405 LEXINGTON AVENUE, 26TH FLOOR, NEW YORK NY 10174
Photios Frank Georgiou	director	405 LEXINGTON AVENUE, 26TH FLOOR, NEW YORK NY 10174
Emmanuel Tsoupanarias	director, officer: Chief Executive Officer	405 LEXINGTON AVENUE, 26TH FLOOR, NEW YORK NY 10174
Leonard Friedman	director	405 LEXINGTON AVENUE, 26TH FLOOR, NEW YORK NY 10174
Marvin Maslow	director, 10 percent owner, officer: Chief Executive Office	MANHATTAN SCIENTIFICS INC, 541 FIFTH AVE STE 36F, NEW YORK NY 10022
David Teich	director, officer: Treasurer	MANHATTAN SCIENTIFICS INC, 541 FIFTH AVE STE 36F, NEW YORK NY 10022
Ralph Anderson	director	641 FIFTH AVENUE SUITE 36F, NEW YORK NY 10022
Larry H Schatz	director	152 W. 57TH STREET, 31ST FLOOR, NEW YORK NY 10019
Marty Steinberg	10 percent owner	1111 BRICKELL AVENUE SUITE 2500, MIAMI FL 33131
Scott Bach	director, officer: Secretary	MANHATTAN SCIENTIFICS INC, 541 FIFTH AVE STE 36F, NEW YORK NY 10022

Manhattan Scientifics (Manhattan Scientifics) Headlines

No Headlines